Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | PPIA | P62937 | 2/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832165 | 1.00 | LTB4R (0.42) | LTB4RLTB4R2PLA2G2ALRRK2MAPK14 | |
| SCHEMBL25606378 | 0.90 | LTB4R (0.41) | LTB4RLTB4R2PLA2G2ALRRK2ALKBH1 | |
| SCHEMBL26612358 | 0.85 | LTB4R (0.42) | LTB4RLTB4R2PLA2G2AMAPK14ALKBH1 | |
| SCHEMBL25606389 | 0.78 | L3MBTL1 (0.35) | LTB4RLTB4R2LRRK2ALKBH1ALDH1A1 | |
| SCHEMBL25606407 | 0.76 | BRD4 (0.37) | LTB4RLTB4R2PLA2G2AALKBH1BRD4 | |
| SCHEMBL25606395 | 0.75 | SMN1; SMN2 (0.44) | LTB4RLTB4R2ALKBH1BRD4PTGER1 | |
| SCHEMBL30368570 | 0.75 | LRRK2 (0.46) | LRRK2BRD4PPIA | |
| SCHEMBL24499446 | 0.75 | TDP1 (0.38) | LTB4RLTB4R2MAPK14BRD4P2RX7 | |
| SCHEMBL23819785 | 0.74 | LTB4R (0.52) | LTB4RLTB4R2PLA2G2APTGER1 | |
| SCHEMBL23805215 | 0.70 | LTB4R (0.48) | LTB4RLTB4R2PLA2G2APTGER1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-06-20 | — | — | US | disclosed |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-03-28 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4255422-A1 | NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | Mydecine Innovations Group Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101722-A1 | NOVEL AZA-SUBSTITUTED PSILOCIN ANALOGS AND METHODS OF SYNTHESIZING THE SAME | MEDECINE INNOVATIONS GROUP INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022120181-A1 | NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | MYDECINE INNOVATIONS GROUP INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120181-A1 | NOVEL PSILOCIN ANALOG COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | MYDECINE INNOVATIONS GROUP INC. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | LTB4R 3523/4885LTB4R2 3775/4885PLA2G2A 979/4885 |
| US-20230348380-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | LTB4R 3523/4885LTB4R2 3775/4885PLA2G2A 979/4885 |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | LTB4R 4033/4885LTB4R2 4217/4885PLA2G2A 1215/4885 |
| US-20230271924-A1 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | PSAP, ABCG2, PSAT1 | LTB4R 2989/4885LTB4R2 2950/4885PLA2G2A 405/4885 |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | LTB4R 4033/4885LTB4R2 4217/4885PLA2G2A 1215/4885 |
| US-11939292-B1 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | LTB4R 4033/4885LTB4R2 4217/4885PLA2G2A 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.